• Ciprofloxacin Hydrochloride: Applied Workflows and Single-Ce

  2026-05-07

  Ciprofloxacin hydrochloride stands apart as a fluoroquinolone antibiotic with dual antibacterial and immunomodulatory properties, enabling advanced research on DNA replication inhibition and cell fate modulation. Explore evidence-based protocols, troubleshooting tips, and single-cell innovations that elevate experimental reproducibility and interpretation.

• Caspofungin: Applied Antifungal Workflows for Candida Resear

  2026-05-06

  Caspofungin, a benchmark lipopeptide antifungal drug, empowers research teams to dissect fungal cell wall biosynthesis and tackle azole-resistant Candida infections with high reproducibility. This article translates advanced study findings into actionable protocols, troubleshooting tactics, and comparative insights for optimizing antifungal assays.

• OSMI-1: Precision O-GlcNAc Transferase Inhibition in Preecla

  2026-05-06

  Explore how OSMI-1, a potent O-GlcNAc transferase inhibitor, uniquely enables mechanistic studies of trophoblast ferroptosis and protein O-GlcNAcylation in preeclampsia. This article offers advanced assay guidance and strategic context beyond standard protocols.

• H3K18 Lactylation Drives NOD2-Dependent Astrocyte Pyroptosis

  2026-05-05

  Li et al. uncover a novel epigenetic mechanism by which H3K18 lactylation upregulates NOD2, promoting pyroptosis in astrocytes during bilirubin encephalopathy. Their findings deepen understanding of neuroinflammation in neonatal hyperbilirubinemia and suggest potential therapeutic intervention points.

• Cytoskeleton Dependence in Mechanical Stress-Induced Autopha

  2026-05-05

  This study provides direct evidence that the cytoskeleton—particularly microfilaments—plays a central role in autophagy triggered by mechanical stress. Using targeted chemical inhibitors and quantitative imaging, the authors reveal a clear mechanistic link between cytoskeletal integrity and cellular autophagic response, clarifying how cells convert physical forces into autophagic signaling.

• Cisplatin in Translational Oncology: Mechanisms, Evidence, a

  2026-05-04

  This thought-leadership article explores the advanced mechanistic understanding and translational application of Cisplatin (CDDP) in cancer research. Integrating recent findings on apoptosis, chemoresistance, and off-target toxicity—including the emerging role of SMYD2 in cisplatin-induced renal fibrosis—this guide provides researchers with actionable experimental protocols and strategic insight. By referencing APExBIO’s rigorously validated Cisplatin and leveraging internal and external literature, we outline how next-generation oncology research can harness mechanistic depth for clinical impact.

• ARCA EGFP mRNA (5-moUTP): Next-Generation Polyadenylated mRN

  2026-05-04

  Explore the scientific foundations and practical advantages of ARCA EGFP mRNA (5-moUTP), a polyadenylated mRNA tool optimized for fluorescence-based transfection control in mammalian cells. This in-depth piece uniquely dissects storage, stability, and assay reproducibility, setting it apart from previous coverage.

• Comparative Antibacterial Activity of Cefazedone and β-Lacta

  2026-05-03

  This article examines a seminal 1982 study comparing the antibacterial efficacy of N-formimidoyl thienamycin (MK0787) to other β-lactam antibiotics, including cefazedone. The findings clarify cefazedone's position among first-generation cephalosporins and offer methodological benchmarks for in vitro antibacterial testing and clinical translation.

• RSL3: Selective Glutathione Peroxidase 4 Inhibitor for Ferro

  2026-05-02

  (1S,3R)-RSL3 is a highly selective glutathione peroxidase 4 inhibitor that robustly induces ferroptosis in cancer models, particularly those with oncogenic RAS mutations. Its utility as a ferroptosis inducer in cancer research is supported by preclinical data showing tumor growth inhibition and synthetic lethality. RSL3's mechanism, solubility, and safety profile make it a preferred tool for dissecting oxidative stress pathways.

• LGK-974: Precision PORCN Inhibitor for Wnt Pathway Research

  2026-05-01

  Unlock potent, selective blockade of the Wnt pathway using LGK-974, a highly specific PORCN inhibitor with proven efficacy in complex tumor models. This guide delivers actionable protocols, troubleshooting insights, and workflow enhancements—empowering researchers to dissect Wnt-driven cancer mechanisms with confidence.

• Metronidazole as an OAT3 Inhibitor: Transforming Research Pr

  2026-05-01

  Explore how Metronidazole, a potent OAT3 inhibitor, is redefining transporter-targeted research and drug-drug interaction modeling. This article offers in-depth protocol guidance and scientific insights beyond typical use cases.

• MDM1 Overexpression Enhances Chemoradiotherapy Sensitivity i

  2026-04-30

  This article analyzes how MDM1 overexpression increases p53-mediated apoptosis and boosts chemoradiotherapy efficacy in colorectal cancer (CRC) cells. The study identifies MDM1 as a promising predictive biomarker and mechanistic target to overcome therapeutic resistance in CRC.

• Bradykinin: Endothelium-Dependent Vasodilator in Research

  2026-04-30

  Bradykinin (SKU BA5201) enables researchers to model endothelium-dependent vasodilation, vascular permeability, and smooth muscle contraction in controlled laboratory systems. It is best suited for cardiovascular, inflammation, and pain mechanism studies demanding precise modulation of endothelial signaling. Use is not recommended for diagnostic or therapeutic applications.

• Z-IETD-FMK: Advancing Caspase-8 Inhibition in Immune Researc

  2026-04-29

  Z-IETD-FMK (Benzyloxycarbonyl-Ile-Glu(OMe)-Thr-Asp(OMe)-fluoromethylketone) enables precise, robust modulation of apoptosis and immune cell signaling. Discover how optimized workflows and strategic troubleshooting maximize its utility for T cell proliferation inhibition, NF-κB signaling studies, and beyond.

• 3-Deazaneplanocin (DZNep): Epigenetic Modulation in Cancer R

  2026-04-29

  This thought-leadership article examines the scientific and translational promise of 3-Deazaneplanocin (DZNep), focusing on its dual mechanistic actions as an epigenetic modulator and its strategic applications in cancer research. With mechanistic depth, protocol guidance, and evidence-based perspective, the article provides actionable insights for translational researchers aiming to target tumor heterogeneity and cancer stem cells, while also mapping the competitive and clinical context.

11492 records 1/767 page Next 12345 下5页 Last page